Kevin DeGeeter
Stock Analyst at Oppenheimer
(2.80)
# 1,876
Out of 4,711 analysts
44
Total ratings
33.33%
Success rate
52.16%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.26 | +1,646.03% | 1 | Apr 19, 2022 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Perform | n/a | $8.21 | - | 1 | Mar 22, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $5.75 | +317.39% | 4 | Feb 25, 2022 | |
| NVCR NovoCure | Upgrades: Outperform | $98 | $30.80 | +218.18% | 3 | Feb 2, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $18.34 | +581.57% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.26 | +696.46% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $8.78 | +116.40% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $0.96 | - | 1 | Oct 1, 2021 | |
| PRTG Portage Biotech | Initiates: Outperform | $600 | $5.96 | +9,967.11% | 1 | Sep 21, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $186.78 | -57.61% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $59.40 | +160.94% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.45 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.39 | +469.48% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $255 | $0.32 | +80,240.26% | 1 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $180 | $0.92 | +19,465.22% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $56.50 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.85 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $11.56 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $0.24 | +21,176.60% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.20 | +7,592.31% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.70 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $150 | $0.16 | +93,650.00% | 1 | Aug 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $23.22 | +868.99% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $13.36 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.28 | - | 2 | Jan 4, 2017 |
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.26
Upside: +1,646.03%
ORIC Pharmaceuticals
Mar 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.21
Upside: -
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $5.75
Upside: +317.39%
NovoCure
Feb 2, 2022
Upgrades: Outperform
Price Target: $98
Current: $30.80
Upside: +218.18%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $18.34
Upside: +581.57%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.26
Upside: +696.46%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $8.78
Upside: +116.40%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.96
Upside: -
Portage Biotech
Sep 21, 2021
Initiates: Outperform
Price Target: $600
Current: $5.96
Upside: +9,967.11%
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $186.78
Upside: -57.61%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $59.40
Upside: +160.94%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $0.45
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $4.39
Upside: +469.48%
Apr 30, 2021
Initiates: Outperform
Price Target: $255
Current: $0.32
Upside: +80,240.26%
Mar 2, 2021
Initiates: Outperform
Price Target: $180
Current: $0.92
Upside: +19,465.22%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $56.50
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.85
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $11.56
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $50
Current: $0.24
Upside: +21,176.60%
Apr 8, 2020
Initiates: Outperform
Price Target: $15
Current: $0.20
Upside: +7,592.31%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.70
Upside: -
Aug 3, 2017
Initiates: Buy
Price Target: $150
Current: $0.16
Upside: +93,650.00%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $23.22
Upside: +868.99%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $13.36
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $5.28
Upside: -